skip to content

At-a-Glance

Issue No. 27 | December 1, 2017

News and Features

AIDSinfo Marks World AIDS Day with the Release of New Consumer Education Materials

On World AIDS Day, AIDSinfo is pleased to introduce the latest additions to the AIDSinfo library of consumer education materials.

  • HIV and Kidney Disease fact sheet: This fact sheet provides basic information about HIV and kidney disease, including risk factors, symptoms, and treatment options. The fact sheet also offers people living with HIV tips on how to reduce their risk of kidney disease.
  • PrEP vs. PEP infographic: This infographic explains the difference between PrEP and PEP, including who each HIV prevention method is intended for and how each is taken.
Visit the Understanding HIV/AIDS section of the AIDSinfo website to browse the complete collection of consumer education materials, including fact sheets, infographics, and a glossary of HIV/AIDS-related terms. Visit infoSIDA to view the materials in Spanish.

FDA Approves Juluca, the First Two-Drug Regimen to Treat Certain Adults with HIV

On November 21, 2017, the U.S. Food and Drug Administration (FDA) approved Juluca, the first complete treatment regimen containing only two drugs to treat certain adults with HIV, instead of the three or more drugs included in standard HIV treatment.

Juluca is a fixed-dose tablet containing two previously approved drugs (dolutegravir and rilpivirine). Juluca is indicated as a complete regimen for the treatment of HIV-1 infection in adults whose HIV is currently suppressed on a stable regimen for at least 6 months, with no history of treatment failure and no known substitutions associated with resistance to the individual components of Juluca.

The Juluca label is available on the FDA website.

For more information, view the FDA press release and the AIDSinfo patient fact sheet on Juluca.

Recent HIV News from CDC and NIAID

From CDC:

From NIAID: